Skip to main content

Volume 18 Supplement 2

Sepsis 2014

  • Poster presentation
  • Published:

More effective use of polymyxin-B hemoperfusion for nonoperation cases


Direct hemoperfusion with polymyxin-B has been reported to improve hemodynamics in postsurgical patients. In 2012, the Japanese Guidelines for the Management of Sepsis were published and mention the efficacy of polymyxin-B direct hemoperfusion. But how to use and the target patients are varied by facilities. We investigated the effective use of polymyxin-B direct hemoperfusion in nonsurgical patients.


We analyzed retrospectively all septic shock patients who were treated with polymyxin-B hemoperfusion between January 2008 and December 2012.We checked their mean arterial pressure (MAP), and vasopressor requirement every 30 minutes until stopping treatment.


There were 32 patients under treatment and 11 patients did not need surgical treatment. Even in the nonsurgical group, hemodynamic states and vasopressor requirement was improved after polymyxin-B hemoperfusion started. And the effects were continued over 120 minutes. A second plolymyxin-B hemoperfusion treatment underwent in nine patients. In second treatment, MAP increased in the nonsurgical group greater than in the postsurgical group.


Polymyxyn-B direct hemoperfusion improves hemodynamic status even in nonsurgical patients. A second polymyxin-B direct hemoperfusion is effective especially in nonsurgical septic shock patients. And if its hemodynamic effect was significantly, long-time treatment should be considered.

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yahata, M., Sakamoto, Y., Inoue, S. et al. More effective use of polymyxin-B hemoperfusion for nonoperation cases. Crit Care 18 (Suppl 2), P32 (2014).

Download citation

  • Published:

  • DOI: